The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design

There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines featur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the American Thoracic Society 2020-07, Vol.17 (7), p.879-891
Hauptverfasser:	Angus, Derek C, Berry, Scott, Lewis, Roger J, Al-Beidh, Farah, Arabi, Yaseen, van Bentum-Puijk, Wilma, Bhimani, Zahra, Bonten, Marc, Broglio, Kristine, Brunkhorst, Frank, Cheng, Allen C, Chiche, Jean-Daniel, De Jong, Menno, Detry, Michelle, Goossens, Herman, Gordon, Anthony, Green, Cameron, Higgins, Alisa M, Hullegie, Sebastiaan J, Kruger, Peter, Lamontagne, Francois, Litton, Edward, Marshall, John, McGlothlin, Anna, McGuinness, Shay, Mouncey, Paul, Murthy, Srinivas, Nichol, Alistair, O'Neill, Genevieve K, Parke, Rachael, Parker, Jane, Rohde, Gernot, Rowan, Kathryn, Turner, Anne, Young, Paul, Derde, Lennie, McArthur, Colin, Webb, Steven A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive Clinical Trials as Topic Anti-Bacterial Agents - therapeutic use Antiviral Agents - therapeutic use Betacoronavirus Clinical Study Design Clinical trials Community-Acquired Infections - therapy Coronavirus Infections - therapy COVID-19 Evidence-Based Medicine Humans Influenza, Human - therapy Intensive care Medical treatment Pandemics Pneumonia Pneumonia - therapy Pneumonia, Viral - therapy Point-of-Care Systems Randomized Controlled Trials as Topic SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!